Equity Research, Broker Reports, and media content on Allergy Therapeutics plc

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Allergy Therapeutics plc
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Allergy Therapeutics plc

Company Profile

  • Personnel
  • Manuel Llobet , CEO
  • Nicolas Wykeman, Finance Director

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Allergy Therapeutics plc. We currently have 281 research reports from 11 professional analysts.

  • Open: N/A
  • Range Today: N/A
  • 52 Week: 12.4/35.9p
  • Daily Volume: N/A
  • Daily Liquidity: (0.09%)
  • # Shares: 641.8m
  • Market Cap: £240.7m
  • Latest PE (hist): 37.53
  • Div Yield:
Date Source Announcement
16Sep21 07:00 RNS Allergy Therapeutics - ImmunoBON voted Most Innovative Product of 2021
13Sep21 07:00 RNS Allergy Therapeutics - Secondary endpoints from VLP Peanut 001
09Sep21 07:00 RNS Allergy Therapeutics - Allergy to Present at H.C. Wainwright Conference
07Sep21 07:00 RNS Allergy Therapeutics - Allergy to host KOL webinar on VLP Peanut
03Aug21 07:00 RNS Allergy Therapeutics - Successful primary outcome of VLP Peanut 001
02Aug21 10:57 RNS Allergy Therapeutics - Total Voting Rights
14Jul21 07:00 RNS Allergy Therapeutics - Trading update for the year ended 30 June 2021
  • Frequency of research reports


  • Research reports on

    Allergy Therapeutics plc

  • Providers covering

    Allergy Therapeutics plc